Search criteria | ||||
CO71 Investigating the Secondary Care System Burden of Glycogen Storage Disease Type IA (GSDIA) Using the HES Database | ||||
E Kruger S Chavda RN Gupta V Valayannopoulos | ||||
Ultragenyx Pharmaceutical Inc., Novato, CA, USA IQVIA, London, UK Ultragenyx Pharmaceutical Inc., Cambridge, MA, USA | ||||
Kruger, E et al. Value in Health, Volume 25, Issue 7, S317 |
||||
, Abstract, Article | ||||
, England | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(22)00370-9/pdf#%20 | ||||
Condition | Year | Language | Analysis type | |
, Metabolic Disorders , Rare disease, Rare Diseases | 2022 | English | , Burden of illness, clinical setting: Secondary care, Quality of life | |
Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan | ||||
Toyomi Kamesaki 1, Jun-Ichi Nishimura 2, Hideho Wada 3, Eric Yu 4, Elisa Tsao 5, Jaime Morales 5, Yuzuru Kanakura 2 6 (rwesheorj 4) | ||||
1) Division of Support in Community Medicine, Center for Community Medicine, Regional Medical Center, Center for Regional Medical Care, Jichi Medical University, 3311 - 1 Yakushiji Shimotsuke-shi, Tochigi, Japan 2) Osaka University, Osaka, Japan 3) Kawasaki Medical School, Kurashiki, Japan 4) IQVIA Solutions K.K., Tokyo, Japan 5) Sanofi, Waltham, MA, USA 6) Sumitomo Hospital, Osaka, Japan | ||||
International Journal of Hematology |
||||
, Article | ||||
, Japan | ||||
Abstract: https://link.springer.com/article/10.1007%2Fs12185-020-02899-6 | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2020 | English | , Retrospective database analysis | |
Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal | ||||
Max Schlueter, Amélie Beaudet, Evan Davies, Binu Gurung, Andreas Karabis | ||||
IQVIA, 210 Pentonville Road, London, N1 9JY; IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, Netherlands; Department of Statistical Science, University College London, London, WC1E 6BT, UK. | ||||
, Article | ||||
Abstract: https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01241-4 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Methodology, Rare Diseases | 2020 | English | , Literature Review, Review | |
A network meta analysis comparing C1 and kallikrein inhibitors approved for prophylaxis of hereditary angioedema in the United States | ||||
P. Saharia1, P. Soni2, M. Chatterjee3 | ||||
IQVIA, Gurugram, HR, India; IQVIA, Delhi, India; IQVIA, Gurugram, India | ||||
DOI: https://doi.org/10.1016/j.jval.2019.04.1641 |
||||
, Article | ||||
, USA | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)31833-9/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Rare Diseases | 2019 | English | , Literature Review, Meta analysis | |
Identification of a hereditary angioedema cohort in a US ambulatory EMR database | ||||
Brouwer E, Bratton E, Near A, Lang K, Mack C | ||||
Pharmacoepidemiol Drug Saf 2018; 27 (2): 136-137. |
||||
, Poster | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2018 | English | ||
Rare disease development programs: An update | ||||
Wu J, Want C, Horton DB, Petersen I, Oliveria S, Blackburn S, Jiang J, LoCasale R. | ||||
Pharmacoepidemiol Drug Saf 2018; 27 (2):5. |
||||
, Poster | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2018 | English | ||
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE. | ||||
Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles | ||||
RWI IQVIA France | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases | 2018 | English | , Cost effectiveness, Pricing & Reimbursement, Willingness to pay | |
Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus | ||||
Kabadi S, Yeaw J, Bacani AK, Tafesse E, Bos K, Karkare S, DeKoven M, Vina ER | ||||
AstraZeneca, IQVIA | ||||
Lupus |
||||
, Article | ||||
, USA | ||||
Abstract: http://journals.sagepub.com/doi/abs/10.1177/0961203318790675?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2018 | English | , Cost analysis, Retrospective cohort analysis | |
Health Care Resource Utilization Among a US Cohort Treated for Hereditary Angioedema, 2010–2015 | ||||
Tachdjian R, Johnson KE, Casso D, Oliveria SA, Devercelli G, Jain G. | ||||
Tachdjian R: UCLA School of Medicine; Johnson KE: IQVIA (formerly); Casso D: IQVIA; Oliveria SA: IQVIA; Devercelli G: Shire; Jain G: Shire | ||||
2018 American Academy of Allergy, Asthma and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Patient Registries & Real-World Study Methods, Rare Diseases | 2018 | English | , Cost analysis, Database Study, Epidemiological study, Retrospective database analysis | |
Demographic Characteristics and Treatment Patterns among Patients Treated for Hereditary Angioedema in a U.S. Cohort, 2006-2015 | ||||
Tachdjian R, Johnson KE, Casso D, Oliveria SA, Devercelli G, Jain G | ||||
Tachdjian R: UCLA School of Medicine (Department of Medicine and Pediatrics), Johnson KE: IQVIA (formerly); Casso D: IQVIA; Oliveria SA: IQVIA; Devercelli G: Shire; Jain G: Shire. | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2018 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis | |
High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project | ||||
Rito Bergemann, James Allsopp, Harvey Jenner, Flora Ashley Daniels, Edmund Drage, Yevgeniy Samyshkin, Claude Schmitt, Steven Wood, David G. Kiely, Allan Lawrie | ||||
"1GlaxoSmithKline, Brentford, Middlesex, UK 2Current affiliation: Evalueserve Life Sciences Healthcare, London, UK 3Scientific Computing Group, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK 4IQVIA, London, UK 5Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK 6National Pulmonary Hypertension Service (Sheffield), Sheffield Pulmonary Vascular Unit, Royal Hallamshire Hospital, Sheffield, UK 7INSIGNEO, University of Sheffield, Sheffield, UK" | ||||
Pulm Circ. 2018 Oct-Dec;8(4):2045894018798613. doi: 10.1177/2045894018798613. |
||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Database Validity and methodology, Rare Diseases, Respiratory disease | 2018 | English | , Retrospective database analysis | |
Real world data from hospital episode statistics can be used to determine patients at risk of idiopathic pulmonary arterial hypertension | ||||
"David G. Kiely MD, Allan Lawrie, Orla Doyle PhD, Valentina Salvatelli PhD, Flora Ashley Daniels PhD, Edmund Drage, Harvey Jenner, John Rigg, Claude Schmitt, Yevgeniy Samyshkin, Rito Bergemann " | ||||
1Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Road, Sheffield, UK; 2Real-World & Analytical Solutions, IQVIA, London, UK; 3GSK, Brentford, Middlesex, UK; 4Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK; 5INSIGNEO, University of Sheffield, Sheffield, UK; 6Evalueserve UK Ltd, London, UK. 1 Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Road, Sheffield, UK. 2 Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK. 3 INSIGNEO, University of Sheffield, Sheffield, UK. 4 Real-World & Analytical Solutions, IQVIA, London, UK. 5 GlaxoSmithKline, Brentford, Middlesex, UK. | ||||
European Respiratory Journal 2018 52: Suppl. 62, PA3082. |
||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Database Validity and methodology, Rare Diseases, Respiratory disease | 2018 | English | , Retrospective database analysis | |
Studies on economic burden of disease using real-world healthcare data in Japan: a systematic review | ||||
WY Kuan 1, Sven Demiya 1, Eric Yu 1, Y Piao 1 (rwesheorj 1) | ||||
1) IQVIA Solutions Japan K.K., Tokyo, Japan | ||||
ISPOR Asia Pacific 2018 Conference |
||||
, Abstract | ||||
, Japan | ||||
Abstract: https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/studies-on-economic-burden-of-disease-using-real-world-healthcare-data-in-japan-a-systematic-review | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2018 | English | , Economic evaluation, Literature Review | |
Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings | ||||
De Bortoli N1, Ripellino C2, Cataldo N3, Marchi S1 | ||||
1 Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy 2 Department of Real World Evidence, HEOR Consultant Freelance, Milan, Italy 3 Department of Real World Evidence, QuintilesIMS, Milan, Italy | ||||
Expert Opinion on Drug Safety. doi: 10.1080/14740338.2017.1376647. [Epub ahead of print] |
||||
, Article | ||||
, Germany, Italy | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28871813 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Gastrointestinal disorders, Rare Diseases | 2017 | English | , Clinical setting: Primary care, Database Study, Real World Data, Real World Evidence, Retrospective cohort analysis, Retrospective database analysis | |
CLOSING THE EVIDENCE GAP FOR ORPHAN DRUGS: DO GERMAN REGULATORY REQUIREMENTS GIVE INCENTIVES FOR HIGH LEVEL EVIDENCE GENERATION? | ||||
Ana Babac, Roger-Axel Greiner, Doreen Bonduelle | ||||
"QuintilesIMS, IMS Health GmbH & Co. OHG, Landshuter Allee 10, 80637 München " | ||||
ISPOR 20th Annual European Congress, Glasgow |
||||
, Poster | ||||
, Germany | ||||
Abstract: https://www.ispor.org/Event/ProgramList/2017Glasgow?type=Poster&sess=II&acode=PHS | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2017 | English | , Pricing & Reimbursement, Retrospective database analysis | |
Creating a Rare Disease Cohort Using Ambulatory Electronic Medical Record (AEMR) Data: Duchenne Muscular Dystrophy (DMD) | ||||
Anderson A1, Casso D1, Susan A. Oliveria SA 1, Douglas Kou T 2 | ||||
1 QuintilesIMS ,2 BMS | ||||
33rd International Conference on Pharmacoepidemiology & Thereputic Risk Management; August, 28, 2017; Montreal, Canada |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Musculoskeletal disease, Patient Registries & Real-World Study Methods, Rare Diseases | 2017 | English | , Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis | |
Creating a Rare Disease Cohort Using Ambulatory Electronic Medical Record Data: Progressive Supranuclear Palsy | ||||
Anderson A, Casso D, Oliveria SA, Kou TD | ||||
AA, DC, and SAO are employees of QuintilesIMS. TDK is an employee of BMS | ||||
33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 26-30, 2017; Montreal, Canada |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders, Patient Registries & Real-World Study Methods, Rare Diseases | 2017 | English | , Epidemiological study, Retrospective cohort analysis | |
Demographic Characteristics and Treatment Patterns Among Patients Treated for Hereditary Angioedema in a US Cohort, 2006-2015 | ||||
Raffi Tachdjian, Karin E. Johnson, Deborah Casso1, Susan A. Oliveria1, Giovanna Devercelli2, Gagan Jain2 | ||||
1, QuintilesIMS ; 2, Shire Development LLC | ||||
North American Rhinology & Allergy Conference, February 9–11, 2017, Puerto Rico |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Patient Registries & Real-World Study Methods, Rare Diseases | 2017 | English | , Epidemiological study, Retrospective cohort analysis | |
Demographic Characteristics and Treatment Patterns Among Patients Treated for Hereditary Angioedema in a US Cohort, 2006–2015 | ||||
Tachdjian R, Johnson KE, Casso D, Oliveria SA, Devercelli G, Jain G | ||||
Tachdjian R, Johnson KE, Casso D, Oliveria SA, Devercelli G, Jain G Tachdjian R: UCLA School of Medicine; Johnson KE: IQVIA (formerly); Casso D: IQVIA; Oliveria SA: IQVIA; Devercelli G: Shire; Jain G: Shire | ||||
North American Rhinology & Allergy Conference: Puerto Rico |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2017 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis | |
Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18. | ||||
Divino V1, DeKoven M2, Kleinrock M3, Wade RL4, Kaura S5. | ||||
1 Victoria Divino (vdivino@us.imshealth.com) is a senior consultant at IMS Health in Fairfax, Virginia. 2 Mitch DeKoven is a principal at IMS Health. 3 Michael Kleinrock is director of research development for the IMS Institute for Healthcare Informatics, in Parsippany, New Jersey. 4 Rolin L. Wade is a senior principal at IMS Health. 5 Satyin Kaura is a senior director at Celgene Corporation, in Summit, New Jersey. | ||||
Health Aff (Millwood). 2016 Sep 1;35(9):1588-94 |
||||
, Article | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2016 | English | , Budget impact | |
Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis. | ||||
Divino V1, DeKoven M2, Kleinrock M3, Wade RL2, Kim T4, Kaura S5. | ||||
1 IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA. vdivino@us.imshealth.com. 2 IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA. 3 IMS Institute for Healthcare Informatics, One IMS Drive, Plymouth Meeting, PA, 19462, USA. 4 Celgene, 6755 Mississauga Rd, Suite 600, Mississauga, ON, L5N 7Y2, Canada. 5 Celgene, 86 Morris Avenue, H-222H, Summit, NJ, 07901, USA. | ||||
Orphanet J Rare Dis. 2016 May 21;11(1):68 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875716/ | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2016 | English | , Budget impact | |